Although disease severity (Scale for Assessment and Rating of Ataxia (SARA)) and change of disease severity (changes of SARA) seemed to be relevant to plasma ISG15 levels (Supplementary Data 6), further examination with a larger number of samples is necessary to determine the utility of ISG15 as a biomarker of SCA1. The gene discussed is ISG15; the disease is Ataxia.